N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, Matthew, De Marco, Anna, Lempp, Florian A., Tortorici, M. Alejandra, Pinto, Dora, Walls, Alexandra C., Beltramello, Martina, Chen, Alex +26 more·2021·Cell
DOI 10.1016/j.cell.2021.03.028

Cited by (909)

Items 101–200 of 909

  1. Spike deep mutational scanning helps predict success of SARS-CoV-2 clades
    Bernadeta Dadonaite, Jack T Brown, Teagan E. McMahon, Ariana Ghez Farrell, Marlin D Figgins, Daniel E. Asarnow, Cameron Stewart, Jimin Lee, Jenni Logue, Trevor Bedford et al. · 2024 · Nature
  2. Neutralizing antibodies for the prevention and treatment of COVID-19
    L. Du, Yang Yang, Xiujuan Zhang · 2021 · Cellular & Molecular Immunology
  3. Antibody and B cell responses to SARS-CoV-2 infection and vaccination
    Katharina Röltgen, Scott Dexter Boyd · 2021 · Cell Host & Microbe
  4. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
    Aurélien Sokal, Giovanna Barba Spaeth, Ignacio Fernández, Matteo Broketa, Imane Azzaoui, Andréa de La Selle, Alexis Vandenberghe, Slim Fourati, Anaïs Roeser, Annalisa Meola et al. · 2021 · Immunity
  5. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
    Wenwei Li, Yaozong Chen, Jérémie Prévost, Irfan Ullah, Maolin Lu, Shang Yu Gong, Alexandra Tauzin, Romain Gasser, Dani Vézina, Sai Priya Anand et al. · 2021 · Cell Reports
  6. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
    Catherine J. Reynolds, Joseph M. Gibbons, Corinna Pade, Kai‐Min Lin, Diana Mūnoz Sandoval, Franziska P. Pieper, David K. Butler, Siyi Liu, Ashley David Otter, George Joy et al. · 2022 · Science
  7. SARS-CoV-2 evolution in the Omicron era
    Cornelius Roemer, Daniel J. Sheward, Ryan Hisner, Federico Gueli, Hitoshi Sakaguchi, Nicholas Frohberg, Josette Schoenmakers, Kenta Sato, Aine Niamh O’Toole, Andrew Rambaut et al. · 2023 · Nature Microbiology
  8. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
    Matthew McCallum, Jessica Bassi, Anna De Marco, Alex Chen, Alexandra C. Walls, Julia di Iulio, M. Alejandra Tortorici, Mary-Jane Navarro, Chiara Silacci-Fregni, Christian Saliba et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  9. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
    Anshumali Mittal, Arun Khattri, Vikash Verma · 2022 · PLoS Pathogens
  10. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
    Hyeseon Cho, K. K. Gonzales-Wartz, De-Li Huang, M. Yuan, M. Peterson, Janie Y. Liang, N. Beutler, J. Torres, Yu Cong, E. Postnikova et al. · 2021 · Science Translational Medicine
  11. Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
    Angel Yun-Kuan Thye, Jodi Woan‐Fei Law, Priyia Pusparajah, Vengadesh Letchumanan, Kok‐Gan Chan, Learn−Han Lee · 2021 · Biomedicines
  12. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
    Yuwen Zhou, Yao Xie, Liansha Tang, Dan Pu, Yajuan Zhu, Jiyan Liu, Xuelei Ma · 2021 · Signal Transduction and Targeted Therapy
  13. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
    Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, Jérémie Prévost, William David Tolbert, Kelly Symmes, Shilei Ding, Mehdi Benlarbi, Shang Yu Gong, Alexandra Tauzin et al. · 2022 · Cell Reports
  14. Recurrent SARS-CoV-2 mutations in immunodeficient patients
    Samuel Wilkinson, Alex Richter, Anna Casey, Husam Kamal Eldin Osman, Jeremy D. Mirza, Joanne Stockton, Josh Quick, Liz Ratcliffe, Natalie Sparks, Nicola Cumley et al. · 2022 · Virus Evolution
  15. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans
    M. Alejandra Tortorici, Amin Addetia, Albert J. Seo, Jack T Brown, Kaiti Sprouse, Jenni Logue, Erica Clark, Nicholas Franko, Helen Y. Chu, David Veesler · 2024 · Immunity
  16. Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
    Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, Ashwini Puniyamurti, Ashley Jia Wen Yip, Vindya Nilakshi Wijesinghe, Zheng Yao Low, Julian Wei-Tze Tang, Vincent T. K. Chow, Sunil Kumar Lal · 2023 · Viruses
  17. The Spike of Concern—The Novel Variants of SARS-CoV-2
    Anna Winger, Thomas Caspari · 2021 · Viruses
  18. SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance
    Yifei Guo, Jiajia Han, Yao Zhang, Jingjing He, Weien Yu, Xueyun Zhang, Jingwen Wu, Shenyan Zhang, Yide Kong, Yue Guo et al. · 2022 · Frontiers in Immunology
  19. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
    H. M. Mengist, Arnaud John Kombe Kombe, D. Mekonnen, Abtie Abebaw, Melese Getachew, Teng-Chuan Jin · 2021 · Seminars in Immunology
  20. SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
    Grabowski, Frederic, Preibisch, Grzegorz, Giziński, Stanisław, Kochańczyk, Marek, Lipniacki, Tomasz · 2021 · Viruses
  21. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies
    Ahmed M. Almehdi, Ghalia Khoder, Aminah Alchakee, Azizeh T. Alsayyid, Nadin H. Sarg, Sameh S. M. Soliman · 2021 · Infection
  22. Cryo-EM structure of the SARS-CoV-2 Omicron spike
    Gabriele Cerutti, Yicheng Guo, Lihong Liu, Liyuan Liu, Zhening Zhang, Yang Luo, Yiming Huang, Harris H. Wang, David D. Ho, Zizhang Sheng et al. · 2022 · Cell Reports
  23. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
    Madeleine F. Jennewein, Anna J. MacCamy, N. R. Akins, Junli Feng, Leah J. Homad, N. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, A. Stuart, V. Edara et al. · 2021 · bioRxiv
  24. Discovery and Characterization of Spike N‐Terminal Domain‐Binding Aptamers for Rapid SARS‐CoV‐2 Detection
    Nataly A. Kacherovsky, Lucy F. Yang, Ha V. Dang, Emmeline L. Cheng, Ian I. Cardle, Alexandra C. Walls, Matthew McCallum, Drew L. Sellers, Frank DiMaio, Stephen J. Salipante et al. · 2021 · Angewandte Chemie International Edition
  25. HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
    Will Fischer, Elena E. Giorgi, Srirupa Chakraborty, Kien Nguyen, Tanmoy Bhattacharya A, James P. Theiler, Pablo A. Goloboff, Hyejin Yoon, Werner Abfalterer, Brian Thomas Foley et al. · 2021 · Cell Host & Microbe
  26. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
    L. Dupont, L. Snell, C. Graham, J. Seow, B. Merrick, T. Lechmere, T. Maguire, Sadie R. Hallett, S. Pickering, T. Charalampous et al. · 2021 · Nature Microbiology
  27. The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape
    Dandan Tian, Yanhong Sun, Jianming Zhou, Qing Ye · 2021 · Journal of Medical Virology
  28. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
    Hikmet Akkız · 2022 · Frontiers in Medicine
  29. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike
    Victoria Stalls, Jared J. Lindenberger, S. Gobeil, Rory C. Henderson, Robert Parks, Maggie Barr, Margaret Deyton, Mitchell Martin, Katarzyna Janowska, Xiao Huang et al. · 2022 · Cell Reports
  30. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
    Marta Alenquer, Filipe Ferreira, Diana Lousa, Mariana Valério, Mónica Medina-Lopes, Marie‐Louise Bergman, Juliana Gonçalves, Jocelyne Demengeot, Ricardo B. Leite, Jingtao Lilue et al. · 2021 · PLoS Pathogens
  31. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
    Prerna Arora, Lu Zhang, Cheila Rocha, Anzhalika Sidarovich, Amy Madeleine Kempf, Sebastian R. Schulz, Anne Cossmann, Bernhard Manger, Eva Baier, Björn Tampe et al. · 2022 · The Lancet Infectious Diseases
  32. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
    Khadija Khan, Gila Lustig, Cornelius Roemer, Kajal Reedoy, Zesuliwe Jule, Farina Karim, Yashica Ganga, Mallory P. Bernstein, Zainab Baig, Laurelle Jackson et al. · 2023 · Nature Communications
  33. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding
    Dhiraj Mannar, James W. Saville, Xing Quan Zhu, Shanti Swaroop Srivastava, Alison Berezuk, Steven Zhou, Katharine S. Tuttle, Andrew Kim, Wei Li, Dimiter Stanchev Dimitrov et al. · 2021 · Cell Reports
  34. Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants
    James W. Saville, Dhiraj Mannar, Xing Quan Zhu, Shanti Swaroop Srivastava, Alison Berezuk, Jean‐Philippe Demers, Steven Zhou, Katharine S. Tuttle, Inna Sekirov, Andrew Kim et al. · 2022 · Nature Communications
  35. Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
    Marco Aurelio Díaz-Salinas, Qi Li, Monir Ejemel, Leonid Yurkovetskiy, Jeremy Luban, Kuang Shen, Yang Wang, James B. Munro · 2022 · eLife
  36. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein
    M. Alejandra Tortorici, Alexandra C. Walls, Anshu Joshi, Young‐Jun Park, Rachel T. Eguia, Marcos C. Miranda, Elizabeth Kepl, Annie M. Dosey, Terry Stevens‐Ayers, Michael J. Boeckh et al. · 2022 · Cell
  37. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma
    Vítor Borges, Joana Isidro, Mário Cunha, Daniela Cochicho, Luís Martins, Luís Banha, Margarida Figueiredo, Leonor Rebelo, Maria Céu Trindade, Sílvia Duarte et al. · 2021 · mSphere
  38. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
    Martin, Darren P, Weaver, Steven, Tegally, Houryiah, San, Emmanuel James, Shank, Stephen D, Wilkinson, Eduan, Lucaci, Alexander G, Giandhari, Jennifer, Naidoo, Sureshnee, Pillay, Yeshnee et al. · 2021
  39. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
    Dennis Lapuente, Thomas Winkler, Matthias Tenbusch · 2023 · Cellular and Molecular Immunology
  40. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
    2021
  41. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
    Anthony P. West, Joel O. Wertheim, Jade C. Wang, Tetyana I. Vasylyeva, Jennifer L. Havens, Moinuddin A. Chowdhury, Edimarlyn Gonzalez, Courtney E. Fang, Steve S. Di Lonardo, Scott Hughes et al. · 2021 · Nature Communications
  42. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies
    Ceri Alan Fielding, Pragati Sabberwal, James C. Williamson, Edward J. D. Greenwood, Thomas W. M. Crozier, Wioleta Milena Zelek, Jeffrey Seow, Carl Graham, Isabella Huettner, Jonathan D. Edgeworth et al. · 2022 · eLife
  43. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
    Daniel J. Sheward, Changil Kim, Roy A. Ehling, Alec P. Pankow, Xaquín Castro Dopico, Robert Dyrdak, Darren Patrick Martin, Sai T. Reddy, Joakim Dillner, Gunilla B. Karlsson Hedestam et al. · 2022 · The Lancet Infectious Diseases
  44. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
    Filippo Bianchini, Virginia Crivelli, Morgan E. Abernathy, Concetta Guerra, Martin Palus, Jonathan Muri, Harold Marcotte, Antonio Piralla, Mattia Pedotti, Raoul De Gasparo et al. · 2023 · Science Immunology
  45. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
    Nicholas K. Hurlburt, Leah J. Homad, Irika R. Sinha, Madeleine F. Jennewein, Anna J. MacCamy, Yu-Hsin Wan, Jim B. Boonyaratanakornkit, Anton M. Sholukh, Abigail M. Jackson, Pan-Pan Zhou et al. · 2022 · Communications Biology
  46. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion
    Mohd Zulkifli Salleh, Jeremy P. Derrick, Zakuan Zainy Deris · 2021 · International Journal of Molecular Sciences
  47. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
    Lok Bahadur Shrestha, Nicodemus T. Tedla, Rowena Anne Bull · 2021 · Frontiers in Immunology
  48. Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
    Aakriti Dubey, Shweta Choudhary, Pravindra Kumar, Shailly Tomar · 2021 · Current Microbiology
  49. Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer
    Dillon S. McBride, Sofya K. Garushyants, John Franks, Andrew F. Magee, Steven H. Overend, Devra D. Huey, Amanda M. Williams, Seth A. Faith, Ahmed Kandeil, Sanja Trifkovic et al. · 2023 · Nature Communications
  50. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
    Acevedo, Mónica L., Alonso-Palomares, Luis, Bustamante, Andrés, Gaggero, Aldo, Paredes, Fabio, Cortés, Claudia P., Valiente-Echeverría, Fernando, Soto-Rifo, Ricardo · 2021
  51. SARS-CoV-2 evolution on a dynamic immune landscape
    Nomenjanahary Alexia Raharinirina, Nils Gubela, Daniela Börnigen, Maureen Rebecca Smith, Djin‐Ye Oh, Matthias Budt, Christin Mache, Claudia Schillings, Stephan Fuchs, Ralf Dürrwald et al. · 2025 · Nature
  52. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor-binding domain
    K. Nabel, S. Clark, S. Shankar, Junhua Pan, L. Clark, Pan Yang, A. Coscia, Lindsay G. A. McKay, Haley Varnum, Vesna Brusic et al. · 2021 · Science
  53. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein
    Valeria Calvaresi, Antoni G. Wrobel, Joanna Toporowska, Dietmar Hammerschmid, Katie J. Doores, Richard T. Bradshaw, Ricardo B. Parsons, Donald J. Benton, Chloë Roustan, Eamonn Reading et al. · 2023 · Nature Communications
  54. Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry
    Shiyou Zhu, Ying Liu, Zhuo Long Zhou, Zhiying Zhang, Xia Xiao, Zhiheng Liu, Ang Chen, Xiaojing Dong, Feng Tian, Shihua Chen et al. · 2021 · Science China Life Sciences
  55. Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker
    Jayanthi S. Shastri, Swapneil Parikh, Veena Aggarwal, Sachee R Agrawal, Nirjhar Chatterjee, Rajit J. Shah, Priti Devi, Priyanka Mehta, Rajesh Pandey · 2021 · Frontiers in Medicine
  56. An early warning system for emerging SARS-CoV-2 variants
    Lorenzo Subissi, Anne von Gottberg, Lipi Thukral, Nathalie Worp, Bas B. Oude Munnink, Surabhi Rathore, Laith Jamal Abu-Raddad, Ximena Aguilera, Erik Alm, Brett Nicholas Archer et al. · 2022 · Nature Medicine
  57. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough
    Mlcochova, Petra, Kemp, Steven, Dhar, Mahesh Shanker, Papa, Guido, Meng, Bo, Mishra, Swapnil, Whittaker, Charlie, Mellan, Thomas, Ferreira, Isabella, Datir, Rawlings et al. · 2021
  58. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines
    John E. Bowen, Young‐Jun Park, Cameron Stewart, Jack T Brown, William K. Sharkey, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Matthew McCallum, M. Alejandra Tortorici et al. · 2022 · Science Immunology
  59. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape
    Jonathan C. Brown, Daniel H. Goldhill, Jie Zhou, Thomas P. Peacock, Rebecca Frise, Niluka Goonawardane, Laury Baillon, Ruthiran Kugathasan, Andreia Pinto, Paul F. McKay et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  60. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
    Prerna Arora, Anzhalika Sidarovich, Nadine Krüger, Amy Madeleine Kempf, Inga Nehlmeier, Luise Graichen, Anna-Sophie Moldenhauer, Martin Sebastian Winkler, Sebastian R. Schulz, Hans‐Martin Jäck et al. · 2021 · Cell Reports
  61. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
    Fred D. Mast, Peter C. Fridy, Natalia E. Ketaren, Junjie Wang, Erica Y. Jacobs, J. P. Olivier, Tanmoy Sanyal, K. Molloy, Fabian Schmidt, Magda Rutkowska et al. · 2021 · eLife
  62. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
    Suryadevara, Naveenchandra, Shrihari, Swathi, Gilchuk, Pavlo, VanBlargan, Laura A., Binshtein, Elad, Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Winkler, Emma S., Chen, Elaine C. et al. · 2021
  63. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
    Dapeng Li, David R. Martinez, Alexandra Schäfer, Haiyan Chen, Maggie Barr, Laura L. Sutherland, Esther Lee, Robert Parks, Dieter Mielke, Whitney Edwards et al. · 2022 · Nature Communications
  64. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
    Mingxi Li, Yifei Ren, Zhen Qin Aw, Bo Chen, Ziqing Yang, Yuqing Lei, Lin Cheng, Qingtai Liang, Junxian Hong, Yiling Yang et al. · 2022 · Nature Communications
  65. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
    Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S. Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S. Katsamba, Fabiana A. Bahna et al. · 2021 · Cell Reports
  66. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
    Shihui Sun, Lei He, Zhongpeng Zhao, Hongjing Gu, Xin De Fang, Tiecheng Wang, Xiaolan Yang, Shaolong Chen, Yong‐Qiang Deng, Jiangfan Li et al. · 2021 · Cellular and Molecular Immunology
  67. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022
    Fonager, Jannik, Bennedbæk, Marc, Bager, Peter, Wohlfahrt, Jan, Ellegaard, Kirsten Maren, Ingham, Anna Cäcilia, Edslev, Sofie Marie, Stegger, Marc, Sieber, Raphael Niklaus, Lassauniere, Ria et al. · 2022 · Eurosurveillance
  68. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains
    Enya Qing, Tom Kicmal, Binod Kumar, Grant M. Hawkins, Emily C. Timm, Stanley M. Perlman, Tom Gallagher · 2021 · mBio
  69. Structural mapping of antibody landscapes to human betacoronavirus spike proteins
    Sandhya Bangaru, Aleksandar Antanasijevic, Nurgun Kose, Leigh M. Sewall, Abigail M. Jackson, Naveenchandra Suryadevara, Xiaoyan Zhan, Jonathan L. Torres, Jeffrey Copps, Alba Torrents de la Peña et al. · 2022 · Science Advances
  70. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus
    Giulia Matusali, Francesca Colavita, Daniele Lapa, Silvia Meschi, Licia Bordi, Pierluca Piselli, Roberta Gagliardini, Angela Corpolongo, Emanuele Nicastri, Andrea Antinori et al. · 2021 · Viruses
  71. Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution
    Wentai Ma, Haoyi Fu, Fanchong Jian, Yunlong Cao, Mingkun Li · 2023 · Nature Ecology & Evolution
  72. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization
    Dhiraj Mannar, James W. Saville, Zehua Sun, Xing Quan Zhu, Michelle M. Martí, Shanti Swaroop Srivastava, Alison Berezuk, Steven Zhou, Katharine S. Tuttle, Michele D. Sobolewski et al. · 2022 · Nature Communications
  73. One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
    Fernando Gónzález‐Candelas, Marie‐Anne Shaw, Tung Gia Phan, Urmila Kulkarni‐Kale, Dimitrios N. Paraskevis, Fabio Luciani, Hirokazu Kimura, Manuela Sironi · 2021 · Infection Genetics and Evolution
  74. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein
    Nimisha Ghosh, Suman Nandi, Indrajit Saha · 2022 · International Immunopharmacology
  75. An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
    Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, Shokouh Rezaei, Vuk Uskoković, Mahdi Alijanianzadeh, Vladimir Nikolaevich Uversky, Seyed Omid Ranaei Siadat, Sina Mozaffari‐Jovin, Yahya Sefidbakht · 2023 · Progress in Biophysics and Molecular Biology
  76. An NTD supersite of attack
    Shee‐Mei Lok · 2021 · Cell Host & Microbe
  77. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
    A. Wheatley, P. Pymm, R. Esterbauer, M. Dietrich, W. Lee, D. Drew, Hannah G. Kelly, L. Chan, F. Mordant, K. A. Black et al. · 2021 · Cell Reports
  78. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
    Allison J. Greaney, Tyler N. Starr, Rachel T. Eguia, Andrea N. Loes, K. Khan, Farina Karim, S. Cele, J. Bowen, Jennifer K. Logue, D. Corti et al. · 2021 · bioRxiv
  79. The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape
    Pedro Filho Noronha Souza, Felipe Pantoja Mesquita, Jackson L. Amaral, Patrícia G.C. Landim, Karollyny Roger Pereira Lima, Marília Braga Costa, Izabelle Rocha Farias, Mônica O. Belém, Yago O. Pinto, H. H. T. Moreira et al. · 2022 · International Journal of Biological Macromolecules
  80. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
    Park, Young-Jun, Pinto, Dora, Walls, Alexandra C., Liu, Zhuoming, De Marco, Anna, Benigni, Fabio, Zatta, Fabrizia, Silacci-Fregni, Chiara, Bassi, Jessica, Sprouse, Kaitlin R. et al. · 2022
  81. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
    V. Dussupt, R. Sankhala, Letzibeth Mendez-Rivera, Samantha M. Townsley, Fabian Schmidt, L. Wieczorek, Kerri G. Lal, G. Donofrio, Ursula Tran, Nathaniel D. Jackson et al. · 2021 · Nature Immunology
  82. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
    Jialing Yin, Chengcheng Li, Chunhong Ye, Zhihui Ruan, Yicong Liang, Yongkui Li, Jianguo Wu, Zhen Luo · 2022 · Computational and Structural Biotechnology Journal
  83. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
    Silvia Meschi, Giulia Matusali, Francesca Colavita, Daniele Lapa, Licia Bordi, Vincenzo Puro, Bruno Daniele Leoni, Claudio Galli, Maria Rosaria Capobianchi, Concetta Castilletti · 2021 · Clinical Chemistry and Laboratory Medicine (CCLM)
  84. Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach
    Taj Mohammad, Arunabh Choudhury, Insan Habib, Purva Asrani, Yash Mathur, Mohd Umair, Farah Anjum, Alaa Shafie, Dharmendra Kumar Yadav, Md. Imtaiyaz Hassan · 2021 · Frontiers in Cellular and Infection Microbiology
  85. SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
    Mohammad Alkhatib, Valentina Svicher, Romina Salpini, Francesca Alessandra Ambrosio, Maria Concetta Bellocchi, Luca Carioti, Lorenzo Piermatteo, Rossana Scutari, Giosuè Costa, Anna Artese et al. · 2021 · Microbiology Spectrum
  86. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
    Kanika Vanshylla, Chengcheng Fan, Marie Wunsch, Nareshkumar Poopalasingam, Matthijs Meijers, Christoph Kreer, Franziska Kleipass, Denis Ruchnewitz, Meryem Seda Ercanoglu, Henning Gruell et al. · 2021 · Cell Host & Microbe
  87. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains
    Apostolos Klinakis, Zoe Cournia, Theodoros N Rampias · 2021 · Computational and Structural Biotechnology Journal
  88. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds et al. · 2021 · Nature Immunology
  89. Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin
    AJ Venkatakrishnan, Praveen Anand, Patrick J. Lenehan, Rohit Suratekar, Bharathwaj Raghunathan, Michiel J.M. Niesen, Venky Soundararajan · 2021
  90. SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA
    Seth A. Hoffman, Cristina Costales, Malaya Kumar Sahoo, Srikanth Palanisamy, Fumiko F. Yamamoto, ChunHong Huang, Michelle Verghese, Daniel Solis, Mamdouh Sibai, Aruna K Subramanian et al. · 2021 · Emerging infectious diseases
  91. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization
    Li Zhang, Zhi-Min Cui, Qian-Qian Li, Bo Wang, Yuan-Ling Yu, Jia-Jing Wu, Jian-Hui Nie, Ru-xia Ding, Hai-Xin Wang, Yue Zhang et al. · 2021 · Communications Biology
  92. Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution
    Ashley L. Taylor, Tyler N. Starr · 2023 · PLoS Pathogens
  93. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
    Liu, Jun, Budylowski, Patrick, Samson, Reuben, Griffin, Bryan D., Babuadze, Giorgi, Rathod, Bhavisha, Colwill, Karen, Abioye, Jumai A., Schwartz, Jordan A., Law, Ryan et al. · 2022 · Science Advances
  94. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
    Anthony P. West, Joel O. Wertheim, Jade C. Wang, Tetyana I. Vasylyeva, Jennifer L. Havens, Moinuddin A. Chowdhury, Edimarlyn Gonzalez, Courtney E. Fang, Steve S. Di Lonardo, Scott Hughes et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  95. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity
    Bo Meng, Rawlings P. Datir, Jinwook Choi, Stephen G. Baker, Gordon Dougan, Christoph Hess, Nathalie Kingston, Paul J. Lehner, Paul Lyons, Nicholas J. Matheson et al. · 2022 · Cell Reports
  96. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
    Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle et al. · 2021 · mBio
  97. Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
    Deepali Gupta, Priyanka Sharma, Mandeep Singh, Mukesh Kumar, Abdul Samath Ethayathulla, Punit Kaur · 2021 · Cellular and Molecular Life Sciences
  98. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
    Fuxing Lou, Maochen Li, Zehan Pang, Lin Jiang, Lin Guan, Lili Tian, Jiaming Hu, Junfen Fan, Huahao Fan · 2021 · Frontiers in Immunology
  99. The way of SARS-CoV-2 vaccine development: success and challenges
    Yetian Dong, Tong Dai, Bin Wang, Lei Zhang, Linghui Zeng, Jun Huang, Haiyan Yan, Long Zhang, Fangfang Zhou · 2021 · Signal Transduction and Targeted Therapy
  100. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
    Yannick Galipeau, Vinayakumar Siragam, Geneviève Laroche, Erika Marion, Matthew Greig, Michaeline McGuinty, Ronald A. Booth, Yves Durocher, Miroslava Čuperlović‐Culf, Steffany A. L. Bennett et al. · 2021 · EBioMedicine